Últimas noticias sobre Celanese (NYSE:CE) Bolsa

Celanese

Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.

Celanese Corp

CEA Industries Inc

Creations Inc

CENTRAL AUTOMOTIVE PRODS by Central Automotive Products Ltd.

Central Automotive Products Ltd

China Eastern Airlines Corp Ltd ADR

CHINA EVERBRIGHT BANK ORD by China Everbright Bank Co Ltd.

China Everbright Bank Co Ltd

CITYCHAMP WATCH & JEWELLE by Citychamp Watch & Jewellery Group Ltd.

Citychamp Watch & Jewellery Group Ltd

Cebu Air Inc

CANASIA ENERGY CORP by CANASIA ENERGY CORP.

CanAsia Energy Corp

Saltbae Capital Corp

CHAOJU EYE CARE HLDGS LTD by CHAOJU EYE CARE HLDGS LTD.

Cecil Bancorp Inc

CECO Environmental Corp

The Central and Eastern Europe Fund, Inc. (The) Common Stock

CENTRAL & EASTERN EUROPE FUND, INC.

Ceres Inc

CEEK VR

UpSnap Inc

Sprott Physical Gold and Silver Trust Units

Sprott Physical Gold and Silver Trust

Global X S&P Catholic Values Developed ex-U.S. ETF

CENTRAL FLA ST BK BELLEVW by Central Florida State Bank (Belleview FL)

COMML NATL FINCL CRP MICH by Commercial National Financial Corp (MI)

Commercial National Financial Corp (MI)

ETRACS Monthly Pay 1.5X Leveraged Closed-End Fund Index ETN

Saba Closed-End Funds ETF

Constellation Energy Corporation - Common Stock

Constellation Energy Corp

CHINA ED GROUP HLDGS LTD by CHINA ED GROUP HLDGS LTD.

China Education Group Holdings Ltd

CERRO GRANDE MINING CORP by Cerro Grande Mining Corp.

Cerro Grande Mining Corp

COSMO ENERGY HLDGS CO LTD by Cosmo Energy Hldgs Co Ltd

Cosmo Energy Holdings Co Ltd

Camber Energy Inc OM PAR $0.001 2022 NEW

COELACANTH ENERGY INC by COELACANTH ENERGY INC

Coelacanth Energy Inc

Camber Energy Inc

CONSOL Energy Inc (New) Com

Cresco Ltd

Celsius - United States Dollar

Celcuity Inc

Bristol-Myers Squibb Company Celegne Contingent Value Rights

Celsius Holdings Inc

CELLCOM ISRAEL LTD ORD by Cellcom Israel, Ltd.

Cellcom Israel Ltd

Cellframe

Celo - United States Dollar

Celer Network - United States Dollar

Centamin PLC

Celularity Inc

PREFERRED COMMERCE INC by Preferred Commerce Inc.

Preferred Commerce Inc

Celexpress Inc

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Technology Holdings Inc

ClearBridge MLP & Midstream Fund Inc Com (New)

iShares J.P. Morgan EM Corporate Bond ETF

CEN Biotech Inc

Caravan Energy Corp Ordinary Shares

CareNet Inc

Cenntro Inc

CENNZnet

Central Garden & Pet Company - Common Stock

Central Garden & Pet Co

Central Garden & Pet Company - Class A Common Stock Nonvoting

Century Aluminum Co

CEO America Inc

CeCors Inc

Cantor Equity Partners, Inc. - Class A ordinary shares

Cantor Equity Partners Inc

REX Crypto Equity Premium Income ETF

Cantor Equity Partners I, Inc. - Class A Ordinary Shares

Cantor Equity Partners I Inc

CEPS PLC

Central Puerto S.A. American Depositary Shares (each represents ten Common Shares)

Central Puerto SA

Crestwood Equity Partners LP Unit Ltd Partnership Int (New)

CERES INC OM NEW

Cere Network

CERES GLOBAL AG CORP ORD by Ceres Global Ag Corp.

Ceres Global Ag Corp

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Holdings Inc

CERo Therapeutics Holdings, Inc. - Warrants

Cerus Corp

Certara Inc

COLOMBIA ENERGY RESOUR by Colombia Energy Resources, Inc.

Colombia Energy Resources Inc

SPDR Series Trust SPDR Bloomberg Enhanced Roll Yield Commodity Strategy No K-1 ETF

CES ENERGY SOLUTIONS ORD by CES Energy Solutions Corp.

CES Energy Solutions Corp

Chesser Resources Ltd

CHINESE ESTS HLDGS ORD by Chinese Estates Holdings Ltd.

Chinese Estates Holdings Ltd

CHINESE ESTS HLD UNSP/ADR by Chinese Estates Holdings Ltd.

CES Synergies Inc

Central Securities Corporation Common Stock

Central Securities Corp

CoinEx Token

ACT Energy Technologies Ltd

ACT ENERGY TECHS LTD by ACT Energy Technologies Ltd.

DriveWealth ETF Trust DriveWealth NYSE 100 Index ETF

CAPITAL CITY ENERGY GROUP by Capital City Energy Group, Inc.

21Shares Core Ethereum ETF

CYBER ENVIRO-TECH INC. by Cyber Enviro-Tech Inc.

Cyber Enviro-Tech Inc

CHINA ECOTOURISM GRP NEW by CHINA ECOTOURISM GROUP LTD.

CETUS CAP ACQUISITION CORP L A

CETUS CAP ACQUISITION CORP RT

CETUS CAP ACQUISITION CORP UNIT 1 CL A & 1 WT EXP & 1 RT

CETUS CAP ACQUISITION CORP WT EXP

WIIM

ASPI

BSLK

CRKN

CRML

CTVA

FEAM

MATV

MEOH

NITO

SCCO

TROX

Shares of companies in the broader materials sector are trading lower amid overall market uncertainty after President Trump confirmed March 4 tariffs.

Piper Sandler analyst Charles Neivert maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Underweight and lowers the price target from $77 to $50.

News

Price Target

Analyst Ratings

Piper Sandler Maintains Underweight on Celanese, Lowers Price Target to $50

Barclays analyst Michael Leithead maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Equal-Weight and lowers the price target from $75 to $59.

Barclays Maintains Equal-Weight on Celanese, Lowers Price Target to $59

In the preceding three months, 14 analysts have released ratings for Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $68.64, a high estimate of $88.00, and a low estimate of $46.00. This current average represents a 25.04% decrease from the previous average price target of $91.57. 
<img src="https://www.benzinga.com/files/images/story/2025/1740405652_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Celanese is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$72.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$56.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$70.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$54.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$46.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$55.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Ghansham Panjabi</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$67.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$88.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$77.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$73.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celanese. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celanese compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Celanese's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Celanese's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Celanese analyst ratings.</a>
<h2>All You Need to Know About Celanese</h2>
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.
<h3>Financial Milestones: Celanese's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Celanese's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -10.5%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.
Net Margin: Celanese's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -80.76%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -30.75%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Celanese's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -7.85%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Celanese's debt-to-equity ratio stands notably higher than the industry average, reaching 2.49. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Celanese Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)

B of A Securities analyst Steve Byrne maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Buy and lowers the price target from $88 to $72.

B of A Securities Maintains Buy on Celanese, Lowers Price Target to $72

Celanese Announces Price Increases Across Range Of Products, Effective Mar. 1

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>BMO Capital analyst Ameet Thakkar downgraded SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) from Market Perform to Underperform and raised the price target from $13 to $15. SolarEdge shares closed at $19.63 on Wednesday. <a href="https://www.benzinga.com/quote/SEDG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Craig-Hallum analyst Jeremy Hamblin downgraded the rating for Axon Enterprise, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) from Buy to Hold and announced a $625 price target. Axon Enterprise shares closed at $593.42 on Wednesday. <a href="https://www.benzinga.com/quote/AXON/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Arun Viswanathan downgraded Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Outperform to Sector Perform and lowered the price target from $84 to $56. Celanese shares closed at $54.91 on Wednesday. <a href="https://www.benzinga.com/quote/CE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Roth MKM analyst Chip Moore downgraded Eos Energy Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) from Buy to Neutral and raised the price target from $4 to $5. Eos Energy Enterprises shares closed at $4.82 on Wednesday. <a href="https://www.benzinga.com/quote/EOSE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Nicholas Campanella downgraded the rating for DTE Energy Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTE#NYSE">DTE</a>) from Overweight to Equal-Weight and lowered the price target from $137 to $135. DTE Energy shares closed at $130.38 on Wednesday. <a href="https://www.benzinga.com/quote/DTE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20145520/image-173-1024x574.png" alt="" class="wp-image-791778" style="width:506px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20145520/image-173-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20145520/image-173-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20145520/image-173-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20145520/image-173.png 1127w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43844722/walmart-dropbox-and-3-stocks-to-watch-heading-into-thursday">Walmart, Dropbox And 3 Stocks To Watch Heading Into Thursday</a></li>
</ul>

Downgrades

Markets

Trading Ideas

AXON

EOSE

SEDG

This Celanese Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Celanese Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) shares are trading lower on Thursday after several analysts slashed price forecasts following fourth-quarter&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/CE/analyst-ratings" rel="noreferrer noopener">earnings&nbsp;reported on Tuesday</a>.&nbsp;
Celanese reported adjusted earnings per share of $1.45, beating analysts' estimate of $1.20 and sales of $2.37 billion, which came&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/25/02/43830036/whats-going-on-with-celanese-shares-wednesday" target="_blank" rel="noreferrer noopener">in line with analysts' estimates</a>.
The company issued guidance for the 2025&nbsp;first-quarter. It sees earnings per share from 25 cents to 50 cents, versus analysts'&nbsp;estimate&nbsp;of $1.63.
Celanese expects its 2025 second-quarter earnings per share to be about&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$1 higher than in the first quarter</a>.&nbsp;
JPMorgan analyst Jeffrey J. Zekauskas lowered the price forecast from $92 to $54 with a Neutral rating.
The analyst writes that Celanese is facing simultaneous challenges in earnings, cash flow, and credit.&nbsp;
The company has exposure to the automotive industry in Europe and the U.S., where demand is expected to remain flat. 
Zekauskas says that the Acetyl Chain segment may experience pricing pressure in 2025, as lower spot pricing in 2024 impacts large customer contract resets.&nbsp;
Additionally, the new acetic acid capacity in China could exert downward pressure on pricing in the medium to long term, adds the analyst.
The analyst says he recommends waiting for greater earnings stability and predictability.&nbsp;
As a result, Zekauskas revised the 2025 EPS forecast down to $6.30 from $9.05.
Other&nbsp;analyst&#8217;s&nbsp;price forecast/rating revisions include:
<ul>
<li>Baird&nbsp;analyst Ghansham Panjabi maintained an Outperform rating and lowered the price forecast from&nbsp;$110&nbsp;to&nbsp;$67.</li>
<li>Wells Fargo&nbsp;analyst Michael Sison reiterated an Equal-Weight rating and cut the price forecast from&nbsp;$75&nbsp;to&nbsp;$55.</li>
<li>UBS&nbsp;analyst analyst Joshua Spector kept Neutral and lowered the price forecast from&nbsp;$72&nbsp;to&nbsp;$60.</li>
<li>Deutsche Bank&nbsp;analyst David Begleiter maintained a Buy rating and slashed the price forecast from&nbsp;$85&nbsp;to&nbsp;$70.</li>
<li>RBC Capital&nbsp;analyst Arun Viswanathan downgraded the company from Outperform to Sector Perform and lowered the price forecast from&nbsp;$84&nbsp;to&nbsp;$56.</li>
</ul>
Investors can gain exposure to the stock via&nbsp;First Trust Materials AlphaDEX Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXZ#NYSE">FXZ</a>) and&nbsp;Pacer CFRA-Stovall Equal Weight Seasonal Rotation ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SZNE#NYSE">SZNE</a>).
Price Action: CE shares are down 5.04% at $52.15 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43856681" target="_blank" rel="noreferrer noopener">Bloom Energy Strengthens 10-Year Equinix Partnership, Deploying Next-Gen Fuel Cells For Data Center Power</a></li>
</ul>
Image: Shutterstock

Equities

Mid Cap

Movers

Pacer CFRA-Stovall Equal Weight Seasonal Rotation ETF

SZNE

Celanese Analysts Brace For Tough 2025 As Price Cuts Pile Up

Celanese shares are trading lower amid continued weakness after the company yesterday issued Q1 EPS guidance below estimates. Also, multiple firms lowered their respective price targets on the stock.

RBC Capital analyst Arun Viswanathan downgrades Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Outperform to Sector Perform and lowers the price target from $84 to $56.

RBC Capital Downgrades Celanese to Sector Perform, Lowers Price Target to $56

Deutsche Bank analyst David Begleiter maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Buy and lowers the price target from $85 to $70.

Deutsche Bank Maintains Buy on Celanese, Lowers Price Target to $70

JP Morgan analyst Jeffrey Zekauskas maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Neutral and lowers the price target from $92 to $54.

JP Morgan Maintains Neutral on Celanese, Lowers Price Target to $54

UBS analyst Joshua Spector maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Neutral and lowers the price target from $72 to $60.

UBS Maintains Neutral on Celanese, Lowers Price Target to $60

Wells Fargo analyst Michael Sison maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Equal-Weight and lowers the price target from $75 to $55.

Wells Fargo Maintains Equal-Weight on Celanese, Lowers Price Target to $55

Baird analyst Ghansham Panjabi maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Outperform and lowers the price target from $110 to $67.

Baird Maintains Outperform on Celanese, Lowers Price Target to $67

Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) shares traded lower on Wednesday after the company 2024 fiscal-year fourth-quarter earnings on Tuesday <a href="http://v">after the market closed</a>.
The Details: Celanese reported adjusted earnings per share of $1.45, beating analysts&#8217; estimate of $1.20. In addition, the company reported sales of $2.37 billion, which came inline with analysts&#8217; estimate.
The company broke down its sales further. It reported $1.28 billion in sales from engineered materials, $1.11 billion in sales from acetyl chain and a $21 million reduction from intersegment eliminations. Furthermore, Celanese reported adjusted EBIT of $156 million.
&#8220;The&nbsp;fourth quarter&nbsp;results developed largely as we expected, despite further demand deterioration that gave no sign of easing. With little indication of near-term recovery, it is our job to drive productivity and earnings growth at Celanese even if fundamental demand remains flat or declines further&#8221;, said Scott Richardson, president and CEO.
&#8220;As we move forward, we are focused on three strategic priorities: intensifying cost reduction, driving growth through our AC optionality model and EM pipeline model, and increasing cash flow to deleverage the balance sheet. We continue to take actions to reduce costs and accelerate growth, and we expect to take additional actions to deliver on our priorities based on evolving business conditions.&#8221;
The company issued guidance for the 2025 fiscal-year first-quarter. It sees earnings per share from 25 cents to 50 cents, versus analysts&#8217; estimate of $1.63. Celanese expects its 2025 second-quarter earnings per share to be about $1 higher than in the first quarter.
Related Link: <a href="https://www.benzinga.com/25/02/43826744/whats-going-on-with-blackrock-stock-today">What&#8217;s Going On With BlackRock Stock Today?</a>
CE Price Action: Celanese shares closed 21.4% lower at $54.91 on Wednesday, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: This illustration was generated using artificial intelligence via Midjourney.

After-Hours Center

What's Going On With Celanese Shares Wednesday?

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Wednesday.
Shares of Gentherm Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/THRM/news">weak quarterly results.</a>
Gentherm shares dipped 17% to $30.00 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) fell 22% to $31.00 in pre-market trading after the company announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 21.1% to $2.70 in today's pre-market trading. InnovAge recently reported worse-than-expected second-quarter financial results.</li>
<li>Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) declined 17.3% to $6.70 in pre-market trading after the company issued first-quarter revenue guidance below estimates and announced a quarter-over-quarter decline in paying app users.</li>
<li>GCL Global Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCL#NASDAQ">GCL</a>) fell 14.7% to $6.40 in pre-market trading after jumping 153% on Tuesday.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) shares dipped 13.5% to $60.50 in pre-market trading after the company issued first-quarter EPS guidance below estimates.</li>
<li>Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) declined 11.9% to $24.94 in pre-market trading following weak quarterly results.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) fell 7.7% to $3.60 in pre-market trading.</li>
<li>Etsy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) declined 6.8% to $53.35 in pre-market trading after reporting a 6.8% YoY decline in fourth-quarter GMV and guiding for a similar YoY GMV decline in the first quarter.</li>
<li>Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) fell 5.4% to $115.50 in pre-market trading after the company reported worse-than-expected first-quarter financial results..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Pre-Market Outlook

BMBL

ETSY

INNV

SLSR

SUPN

THRM

Gentherm Posts Downbeat Results, Joins Celanese, Bumble And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Celanese shares are trading lower after the company issued Q1 EPS guidance below estimates.

Shares of Global Blue Group Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) rose sharply during Wednesday's pre-market trading session after the company announced it will be acquired by Shift4 for <a href="https://www.benzinga.com/quote/gb/analyst-ratings">$7.50 per share</a>.
Global Blue Group shares jumped 18.3% to $7.37 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Cycurion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCU#NASDAQ">CYCU</a>) rose 132.5% to $7.79 in pre-market trading after dipping 72% on Tuesday.</li>
<li>OSR Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) shares jumped 96.4% to $6.11 in pre-market trading after gaining 3% on Tuesday.</li>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYT#NASDAQ">LYT</a>) gained 52.7% to $0.34 in pre-market trading after dipping 14% on Tuesday.</li>
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) gained 43.3% to $1.55 in pre-market trading. ReShape Lifesciences shares dipped around 54% on Tuesday after the company announced a $6 million public offering of 2,575,107 units at $2.33 per unit.</li>
<li>Sintx Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares climbed 38.3% to $3.90 in pre-market trading. Sintx Technologies announced the issuance of U.S. patent no. 12,239,761 by the United States Patent and Trademark Office.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) gained 35.2% to $2.96 in pre-market trading after gaining around 12% on Tuesday.</li>
<li>TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) gained 33.1% to $0.5444 in pre-market trading after the company guided 2024 sales of $22.5 million and 2H adjusted EBITDA above $2.2 million.</li>
<li>Aditxt, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) gained 22.3% to $0.1345 in pre-market after surging 57% on Tuesday.</li>
<li>Mercurity Fintech Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) rose 14.5% to $8.00. MFH&#8217;s majority-owned subsidiary Aifinity Base Limited plans to manufacture advanced liquid cooling solutions for Nvidia&#xAE; chip-powered AI data centers and high-performance computing.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Movano Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) shares fell 36.4% to $3.25 in pre-market trading.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) shares fell 25.5% to $0.1439 in pre-market trading after gaining around 8% on Tuesday.</li>
<li>Design Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) dipped 24.5% to $3.120 in pre-market trading.</li>
<li>Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) fell 22% to $31.00 in pre-market trading after the company announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 21.1% to $2.70 in today's pre-market trading. InnovAge recently reported worse-than-expected second-quarter financial results.</li>
<li>MGO Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) shares tumbled 20.9% to $0.3680 in pre-market trading after dipping 35% on Tuesday. MGO Global&#8217;s stockholders approved business combination with Heidmar.</li>
<li>Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) declined 17.3% to $6.70 in pre-market trading after the company issued first-quarter revenue guidance below estimates and announced a quarter-over-quarter decline in paying app users.</li>
<li>Gentherm Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) fell 17% to $30.00 in pre-market trading following weak quarterly results.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) shares dipped 13.5% to $60.50 in pre-market trading after the company issued first-quarter EPS guidance below estimates.</li>
<li>Nexa Resources S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEXA#NYSE">NEXA</a>) fell 10.6% to $4.60 in pre-market trading following a 7% decline on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Comments

Celanese

Noticias

Últimas noticias sobre Celanese (NYSE:CE) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL